75 related articles for article (PubMed ID: 10928047)
21. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
22. Anticancer drug delivery with nanoparticles.
Conti M; Tazzari V; Baccini C; Pertici G; Serino LP; De Giorgi U
In Vivo; 2006; 20(6A):697-701. PubMed ID: 17203748
[TBL] [Abstract][Full Text] [Related]
23. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells.
Mai J; Song S; Rui M; Liu D; Ding Q; Peng J; Xu Y
J Control Release; 2009 Nov; 139(3):174-81. PubMed ID: 19576253
[TBL] [Abstract][Full Text] [Related]
24. TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
Yang W; Luo D; Wang S; Wang R; Chen R; Liu Y; Zhu T; Ma X; Liu R; Xu G; Meng L; Lu Y; Zhou J; Ma D
Clin Cancer Res; 2008 Sep; 14(17):5494-502. PubMed ID: 18765541
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic activity of a tumor protease-activated pore-forming toxin.
Potrich C; Tomazzolli R; Dalla Serra M; Anderluh G; Malovrh P; Macek P; Menestrina G; Tejuca M
Bioconjug Chem; 2005; 16(2):369-76. PubMed ID: 15769091
[TBL] [Abstract][Full Text] [Related]
26. Novel polymeric prodrug with multivalent components for cancer therapy.
Khandare JJ; Chandna P; Wang Y; Pozharov VP; Minko T
J Pharmacol Exp Ther; 2006 Jun; 317(3):929-37. PubMed ID: 16469865
[TBL] [Abstract][Full Text] [Related]
27. Antibody conjugates and therapeutic strategies.
McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
[TBL] [Abstract][Full Text] [Related]
28. Syndecan binding sites in the laminin alpha1 chain G domain.
Suzuki N; Ichikawa N; Kasai S; Yamada M; Nishi N; Morioka H; Yamashita H; Kitagawa Y; Utani A; Hoffman MP; Nomizu M
Biochemistry; 2003 Nov; 42(43):12625-33. PubMed ID: 14580209
[TBL] [Abstract][Full Text] [Related]
29. Lysosomal degradation of cholecystokinin-(29-33)-amide in mouse brain is dependent on tripeptidyl peptidase-I: implications for the degradation and storage of peptides in classical late-infantile neuronal ceroid lipofuscinosis.
Bernardini F; Warburton MJ
Biochem J; 2002 Sep; 366(Pt 2):521-9. PubMed ID: 12038963
[TBL] [Abstract][Full Text] [Related]
30. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform.
Hong S; Leroueil PR; Majoros IJ; Orr BG; Baker JR; Banaszak Holl MM
Chem Biol; 2007 Jan; 14(1):107-15. PubMed ID: 17254956
[TBL] [Abstract][Full Text] [Related]
31. A peptide carrier for the delivery of biologically active proteins into mammalian cells.
Morris MC; Depollier J; Mery J; Heitz F; Divita G
Nat Biotechnol; 2001 Dec; 19(12):1173-6. PubMed ID: 11731788
[TBL] [Abstract][Full Text] [Related]
32. The use of biotinylated-EGF-modified gelatin nanoparticle carrier to enhance cisplatin accumulation in cancerous lungs via inhalation.
Tseng CL; Su WY; Yen KC; Yang KC; Lin FH
Biomaterials; 2009 Jul; 30(20):3476-85. PubMed ID: 19345990
[TBL] [Abstract][Full Text] [Related]
33. [Study on third-type immunoliposomes loaded drugs and the targeting in vitro and in vivo].
Hou XP; Zhang YF; Xie SS; Hu X
Yao Xue Xue Bao; 2001 Jul; 36(7):539-42. PubMed ID: 12585089
[TBL] [Abstract][Full Text] [Related]
34. Drug, enzyme and peptide delivery using erythrocytes as carriers.
Millán CG; Marinero ML; Castañeda AZ; Lanao JM
J Control Release; 2004 Feb; 95(1):27-49. PubMed ID: 15013230
[TBL] [Abstract][Full Text] [Related]
35. Pentapeptide YIGSR-mediated HT-1080 fibrosarcoma cells targeting of adriamycin encapsulated in sterically stabilized liposomes.
Lopez-Barcons LA; Polo D; Reig F; Fabra A
J Biomed Mater Res A; 2004 Apr; 69(1):155-63. PubMed ID: 14999763
[TBL] [Abstract][Full Text] [Related]
36. pH-sensitive toxins: interactions with membrane bilayers and application to drug delivery.
Cabiaux V
Adv Drug Deliv Rev; 2004 Apr; 56(7):987-97. PubMed ID: 15066756
[TBL] [Abstract][Full Text] [Related]
37. Vascular targeting as a strategy for cancer therapy.
Schnitzer JE
N Engl J Med; 1998 Aug; 339(7):472-4. PubMed ID: 9700184
[No Abstract] [Full Text] [Related]
38. A biotin-guided fluorescent-peptide drug delivery system for cancer treatment.
Kim T; Jeon HM; Le HT; Kim TW; Kang C; Kim JS
Chem Commun (Camb); 2014 Jul; 50(57):7690-3. PubMed ID: 24898048
[TBL] [Abstract][Full Text] [Related]
39. Laminin-derived peptides: Applications in drug delivery systems for targeting.
Negishi Y; Nomizu M
Pharmacol Ther; 2019 Oct; 202():91-97. PubMed ID: 31158392
[TBL] [Abstract][Full Text] [Related]
40. The future of peptides in cancer treatment.
Kurrikoff K; Aphkhazava D; Langel Ü
Curr Opin Pharmacol; 2019 Aug; 47():27-32. PubMed ID: 30856511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
